XM does not provide services to residents of the United States of America.
F
F

FreseniusMedical

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. STOCKS Nasdaq, Albemarle, Haemonetics

BUZZ-U.S. STOCKS ON THE MOVE-Nasdaq, Albemarle, Haemonetics Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street fell on Tuesday, with weakness in megacap growth stocks such as Apple and Tesla weighing on the Nasdaq, while investors assessed a slew of economic data and awaited remarks from Federal Reserve Chair Jerome Powell.
A
N
S
T
A
F
U
U
D

Dialysis providers gain as investors focus on cardiac benefits after Ozempic's latest data

CORRECTED-(OFFICIAL)-UPDATE 1-Dialysis providers gain as investors focus on cardiac benefits after Ozempic's latest data Corrects paragraph 5 to say Ozempic cut the risk of death from kidney disease and major cardiac events (not just kidney disease) in diabetes patients by 24%, after company corrected its earlier information By Pratik Jain and Bhanvi Satija March 5 (Reuters) - Shares of dialysis services providers jumped between 3% and 12% on Tuesday as latest data from Novo Nordisk's NOVOb.CO h
F
N
D

Dialysis firms gain as Ozempic kidney trial data disappoints some investors

BUZZ-Dialysis firms gain as Ozempic kidney trial data disappoints some investors Updates ** Shares of dialysis firms DaVita DVA.N and U.S.-listed shares of Fresenius Medical FMS.N rise ~7 .2 % and 12 .8% respectively ** Shares of Baxter International BAX.N , which has a kidney care unit that also provides dialysis operations, gain 2 .7 % to ~$43 .6
F
N
D

Dialysis firms gain as Ozempic kidney trial data disappoints

Dialysis firms gain as Ozempic kidney trial data disappoints March 5 (Reuters) - Shares of dialysis services providers jumped in early trading on Tuesday after Novo Nordisk's NOVOb.CO popular diabetes drug Ozempic fell short of some expectations when tested on patients with chronic kidney disease. Colorado-based DaVita DVA.N rose 7.4%, while the U.S.-listed shares of rival Fresenius Medical FMS.N were up 9.5% in early trading.
F
N
D

Fresenius Medical Care Announces Sale Of Dialysis Clinics In Brazil, Colombia, Chile, Ecuador

BRIEF-Fresenius Medical Care Announces Sale Of Dialysis Clinics In Brazil, Colombia, Chile, Ecuador March 5 (Reuters) - FRESENIUS MEDICAL CARE AG FMEG.DE : FMC AG - FRESENIUS MEDICAL CARE ACHIEVES NEXT MILESTONE IN PORTFOLIO OPTIMIZATION PROGRAM, ANNOUNCING SALE OF DIALYSIS CLINICS IN BRAZIL, COLOMBIA, CHILE, ECUADOR FMC AG - DIVESTMENT OF ASSETS INCLUDES FOUR SEPARATE COUNTRY TRANSACTIONS TO DAVITA INC.
F

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.